First Time Loading...

Fuji Pharma Co Ltd
TSE:4554

Watchlist Manager
Fuji Pharma Co Ltd Logo
Fuji Pharma Co Ltd
TSE:4554
Watchlist
Price: 1 529 JPY 0.72% Market Closed
Updated: May 16, 2024
Financials Section:
Income Statement Balance Sheet Cash Flow Statement

Balance Sheet

84.6B
-0.9%
Assets
Growth Rates:
1 Year
+5%
3 Years
+34%
5 Years
+61%
7 Years
+74%
10 Years
+108%
42.6B
-4%
Liabilities
Growth Rates:
1 Year
+1%
3 Years
+92%
5 Years
+160%
7 Years
+135%
10 Years
+163%
42B
+2%
Equity
Growth Rates:
1 Year
+9%
3 Years
+3%
5 Years
+16%
7 Years
+37%
10 Years
+72%

Balance Sheet Decomposition
Fuji Pharma Co Ltd

84.6B
Assets
42.6B
Liabilities
84.6B
Assets
42.6B
Liabilities
Current Assets 40.4B
Cash & Short-Term Investments 2.2B
Receivables 16.7B
Other Current Assets 21.5B
Non-Current Assets 44.2B
Long-Term Investments 6.1B
PP&E 21.2B
Intangibles 10.3B
Other Non-Current Assets 6.5B
Current Liabilities 27.7B
Accounts Payable 6.8B
Accrued Liabilities 264m
Short-Term Debt 11.3B
Other Current Liabilities 9.4B
Non-Current Liabilities 14.9B
Long-Term Debt 12.4B
Other Non-Current Liabilities 2.5B

Balance Sheet
Fuji Pharma Co Ltd

Rotate your device to view
Balance Sheet
Currency: JPY
Sep-2014 Sep-2015 Sep-2016 Sep-2017 Sep-2018 Sep-2019 Sep-2020 Sep-2021 Sep-2022 Sep-2023
Assets
Cash & Cash Equivalents
8 173
5 158
6 815
5 503
6 251
8 494
12 041
10 199
3 546
2 324
Cash Equivalents
8 173
5 158
6 815
5 503
6 251
8 494
12 041
10 199
3 546
2 324
Short-Term Investments
506
506
0
0
0
0
0
0
0
0
Total Receivables
14 344
12 591
13 137
15 156
16 936
12 987
11 708
11 984
12 661
16 520
Accounts Receivables
11 617
12 331
13 067
15 136
16 897
12 944
11 700
11 866
11 734
15 188
Other Receivables
2 727
260
70
20
39
43
8
118
927
1 332
Inventory
9 151
11 395
11 568
11 485
11 284
10 711
10 680
12 006
15 823
19 371
Other Current Assets
994
1 064
789
1 064
456
1 727
546
645
2 697
899
Total Current Assets
33 168
30 714
32 309
33 208
34 927
33 919
34 975
34 834
34 727
39 114
PP&E Net
10 465
10 618
11 016
11 703
11 700
11 718
12 767
14 392
18 762
20 547
PP&E Gross
10 465
10 618
11 016
11 703
11 700
11 718
12 767
14 392
18 762
20 547
Accumulated Depreciation
11 244
12 371
12 281
13 948
15 337
15 916
16 020
16 973
16 875
18 985
Intangible Assets
1 597
1 214
1 124
733
456
1 806
1 755
1 532
660
738
Goodwill
3 030
2 662
1 936
1 976
1 764
1 494
1 144
865
9 744
9 755
Long-Term Investments
93
108
128
58
60
7 342
7 000
7 762
7 339
10 587
Other Long-Term Assets
674
457
1 634
1 873
4 210
4 458
4 321
4 854
4 306
4 591
Other Assets
3 030
2 662
1 936
1 976
1 764
1 494
1 144
865
9 744
9 755
Total Assets
49 027
N/A
45 773
-7%
48 147
+5%
49 551
+3%
53 117
+7%
60 737
+14%
61 962
+2%
64 239
+4%
75 538
+18%
85 332
+13%
Liabilities
Accounts Payable
6 635
6 102
6 291
5 721
6 746
4 813
3 680
5 713
6 249
5 672
Accrued Liabilities
933
755
766
883
1 175
863
438
982
990
883
Short-Term Debt
1 183
0
0
0
0
0
1 000
7 000
8 300
11 300
Current Portion of Long-Term Debt
1 261
1 456
2 308
1 085
537
3 370
2 156
2 521
2 817
5 724
Other Current Liabilities
2 706
2 676
3 374
3 824
3 088
2 966
3 730
3 976
5 619
6 192
Total Current Liabilities
12 718
10 989
12 739
11 513
11 546
12 012
11 004
20 192
23 975
29 771
Long-Term Debt
5 890
4 627
4 787
3 953
4 701
7 697
9 191
9 294
13 571
12 038
Minority Interest
1
1
1
2
2
2
2
1
2
2
Other Liabilities
1 875
1 564
1 395
1 484
1 520
1 665
1 806
2 072
2 186
2 346
Total Liabilities
20 484
N/A
17 181
-16%
18 922
+10%
16 952
-10%
17 769
+5%
21 376
+20%
22 003
+3%
31 559
+43%
39 734
+26%
44 157
+11%
Equity
Common Stock
3 799
3 799
3 799
3 799
3 799
3 799
3 799
3 799
3 799
3 799
Retained Earnings
19 012
20 669
21 944
24 541
27 119
29 243
30 424
24 628
26 546
29 082
Additional Paid In Capital
5 023
5 023
5 023
5 023
5 023
5 841
5 841
4 409
4 409
4 409
Unrealized Security Profit/Loss
9
20
2
8
9
340
650
23
160
2 414
Treasury Stock
0
1 504
1 488
1 476
1 504
78
68
590
579
567
Other Equity
700
585
55
704
902
896
613
457
1 469
2 038
Total Equity
28 543
N/A
28 592
+0%
29 225
+2%
32 599
+12%
35 348
+8%
39 361
+11%
39 959
+2%
32 680
-18%
35 804
+10%
41 175
+15%
Total Liabilities & Equity
49 027
N/A
45 773
-7%
48 147
+5%
49 551
+3%
53 117
+7%
60 737
+14%
61 962
+2%
64 239
+4%
75 538
+18%
85 332
+13%
Shares Outstanding
Common Shares Outstanding
31
30
30
30
30
31
31
24
24
24

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
ALPHA SPREAD
Join more than 137,600+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.